Terminal ileal intubation provides a 0.28% diagnostic yield for clinically significant pathology in asymptomatic patientsColonoscopy technique shows low yield for finding Crohn's disease

This meta-analysis evaluated the clinical utility and diagnostic yield of terminal ileal intubation (TII) in a large cohort of asymptomatic adults. The study population consisted of 25,659 patients undergoing colonoscopy for colorectal cancer screening or postpolypectomy surveillance. Of these, 13,672 patients underwent TII during the procedure. The primary objective was to determine if extending the scope of the examination to the terminal ileum provides significant diagnostic value in asymptomatic populations.

The study specifically looked at the yield of findings when performing TII compared to standard procedures. While the specific comparator group is not reported, the analysis focused on the absolute yields achieved during TII. The primary outcome was the overall diagnostic yield of TII for any ileal finding. The results showed a yield of 1.74% (95% CI, 1.18-2.57). This indicates that while some findings are occasionally detected in the terminal ileum, they are relatively infrequent.

Secondary outcomes focused on the clinical significance of these findings and specific pathologies. The diagnostic yield for clinically significant pathology was reported at 0.28% (95% CI, 0.07-1.05). Furthermore, the specific diagnostic yield for detecting Crohn's disease (CD) was found to be 0.1%, which equates to approximately 1 case per 1000 ileoscopies (95% CI, 0.02-0.44). These figures suggest that the vast majority of findings in the terminal ileum are non-specific and do not necessitate clinical action.

Regarding safety and tolerability, no specific adverse events, serious adverse events, or discontinuation rates were reported in the data provided. The study did not provide specific details on procedure duration impacts or other procedural metrics beyond the diagnostic yields.

These findings suggest that for asymptomatic patients undergoing screening or surveillance, the addition of TII does not significantly increase the detection of actionable pathology. Most identified abnormalities are noted as non-specific. This reinforces the standard of care where routine TII is not required to identify Crohn's disease in this specific patient population.

Methodological limitations were not reported. However, the large sample size of 25,659 patients provides a robust basis for the low yield figures. The clinical implications are clear: because the yield for clinically significant pathology is only 0.28%, routine TII in asymptomatic screening populations may not be necessary to identify Crohn's disease.

Several questions remain regarding the specific types of non-specific findings that constitute the majority of the 1.74% yield. Additionally, it is unclear if the yield changes significantly in symptomatic patients or those with specific risk factors for inflammatory bowel disease. The data confirms that for the general screening population, the diagnostic gain from TII is minimal.